Zantac Update: First Trial Set for Feb. 13, 2023
24 juin 2022 17h01 HE | Baum Hedlund Aristei & Goldman
Oakland, California, June 24, 2022 (GLOBE NEWSWIRE) -- The California State Court Judge overseeing the Ranitidine Products Cases JCCP NO. 5150 issued a pretrial order this week establishing a trial...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
15 févr. 2022 09h00 HE | AXIM BIOTECHNOLOGIES, INC
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab...
logo.jpg
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
03 févr. 2022 05h03 HE | ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01          EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
logo.jpg
Bispecific Antibodies Cancer Immunotherapy Clinical Trials Insight 2028
09 déc. 2021 07h07 HE | KuicK Research
Delhi, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028 Report Analysis and Data Highlights: Research...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
22 juin 2021 09h00 HE | Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
logo.jpg
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
11 mars 2021 05h00 HE | ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
Novavax logo
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
26 févr. 2021 08h23 HE | Novavax, Inc.
Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in JapanTakeda doses first participant in immunogenicity and safety study to support...
monopar.jpg
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
16 févr. 2021 07h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein
24 nov. 2020 08h17 HE | InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
10 sept. 2020 05h46 HE | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...